Cannabis Science Acquires Pet Care Manufacturer and Distributor Equi-Pharm & Enters the $60 Billion Pet Care Industry
COLORADO SPRINGS, Colo., May 7, 2015 /PRNewswire/ -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabis-based medicine and related consulting, is pleased to announce the acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products.
"We are excited about the future of Equi-Pharm under the medical direction and leadership of Cannabis Science, we already have a great response from our customers on the limited sales from our five horse related grooming and health products for the Equestrian market. We are currently developing the first three new cannabinoid-enriched pet products right now and will be available to the pet market within a matter of weeks through our current distribution channels. Right now we have a limited market share across the USAutilizing distributors and retail outlets in California, Kentucky, Ohio, Louisiana, Tennessee, and we just started European expansions. We expect that the enrichment of our current products and the development of our new formulas using Cannabis Science medical expertise we envision substantial growth year by year. Our goal of course, is to push Equi-Pharm and Cannabis Science to the front of the pack in the pet care industry," stated Dana Kennamer, Vice-President of Equi-Pharm, LLC.
"We are very excited to enter this $60 Billion market with the Equi-Pharm team. This new edition to the Cannabis Science family broadens our reach and positions us instantly in an expanding industry. This industry is especially endearing to our Special Senior Advisor, Dr. Roscoe M. Moore Jr., DVM, Ph.D. D.Sc., Assistant U.S. Surgeon General (Retired); who as well, is a Doctor of Veterinary Medicine. Dr. Moore was the former Chief Veterinary Medical Officer for the Commissioned Corps of the United States Public Health Service selected by Surgeon General C. Everett Koop. At one point, Dr. Moore was the highest ranking Doctor of Veterinary Medicine in all of the Uniformed Services, including the Military or Armed Services. Dr. Moore will bring his considerable expertise as a Veterinarian to assist in formulation and development of future animal products that Cannabis Science will make available globally. Spending on animal and pet care products is increasing rapidly as pet and horse owners expand their knowledge and see the benefits of modern science when it comes to the vital health of their companion animals," said Mr. Raymond C. Dabney, Cannabis Science Inc., President & CEO, and Co-Founder.
We are very excited as we are in the process of redesigning our current website and adding some helpful public information and an ecommerce function for our consumers to not only purchase our products through retail outlets and distributors, but the ability purchase our products directly online as well. The general veterinary "divisions" in this animal market space are usually "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "pets" include cats, dogs, pet snakes and the like. We are excited about Cannabis Science bringing new formulas to our product line and can't wait to have them available for our customers" concludes, Ms. Kennamer, Vice-President of Equi-Pharm, LLC.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.